title: Four years experience of primary intra-arterial chemotherapy (PIAC) for locally advanced and recurrent breast cancer.
abstract: OBJECTIVE
  To find a means of achieving operability very quickly without the additional discomfort of prolonging systemic chemotherapy. To improve the patient's quality of life by obtaining quick tumor reduction and decreasing systemic toxicity.
  
  
  METHODS
  From January 1991 to January 1995, 13 patients with locally advanced breast cancer (LABC) and 8 patients with recurrent breast cancer (RBC), were treated by transfemoral Seldinger technique, with the catheter tip placed into the subclavian artery at the basis of the internal mammary artery. The patients received 5-fluorouracil (5FU) 1000 mg, epirubicin (EPI) 30 mg/m2, mitomycin (MMC) 7 mg/m2 over an infusion for 30 minutes. The cycle was repeated every two weeks for three times.
  
  
  RESULTS
  The overall response rate was 62%. Stage IIIb and RBC patients had a response rate of 100% and 25% respectively. In respondent patients a measurable response was seen after the first cycle. Ten patients were radically operated. After a media follow-up of 21 months, the overall survival is 52% at 48 months (68% at 48 months and 65% at 34 months for stage IIIb and RBC patients respectively).
  
  
  CONCLUSIONS
  PIAC is feasible and effective. In LABC patients it reaches 100% of response rate. Systemic toxicity was absent and the local one was mild. The interval between the starting of PIAC and operation is short. There was an optimal compliance of the patients.
authors.affiliation: Divisione di Oncologia Medica, Azienda Ospedaliera C. Poma, Mantova.
authors.forename: M
authors.initials: M
authors.lastname: Cantore
authors.forename: G
authors.initials: G
authors.lastname: Fiorentini
authors.forename: G
authors.initials: G
authors.lastname: Cavazzini
authors.forename: L
authors.initials: L
authors.lastname: Molani
authors.forename: C
authors.initials: C
authors.lastname: Morandi
authors.forename: M
authors.initials: M
authors.lastname: Caforio
authors.forename: G
authors.initials: G
authors.lastname: Caleffi
authors.forename: A
authors.initials: A
authors.lastname: Mambrini
authors.forename: D
authors.initials: D
authors.lastname: Zamagni
authors.forename: F
authors.initials: F
authors.lastname: Smerieri
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D008937:Mitomycins; D015251:Epirubicin; D005472:Fluorouracil